

Comparison Between Continuous Versus Flash Glucose Monitoring in Children, Adolescents, and Young Adults with Type 1 Diabetes: An 8-Week Prospective Randomized Trial

Anissa Messaaoui, M.D.¹, Sylvie Tenoutasse, M.D.¹, Lucia Hajselova¹, M.D., Laurent Crenier, M.D., Ph.D.²

Author Affiliations:¹Diabetology Clinic, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium—Université Libre de Bruxelles (ULB) ; ²Department of Endocrinology, Hôpital Erasme, Brussels, Belgium—Université Libre de Bruxelles (ULB)


Anissa Messaaoui
HUDERF
15 JJ Crocq avenue
1020 Brussels
003224773384
Anissa.messaaoui@huderf.be

Sylvie Tenoutasse
HUDERF
15 JJ Crocq avenue
1020 Brussels
003224773185
Sylvie.tenoutasse@huderf.be

Lucia Hajselova
HUDERF
15 JJ Crocq avenue
1020 Brussels
003224773382
lucia.hajselova@huderf.be

Laurent Crenier
Hôpital Erasme
808 Lennik route
1070 Brussels
003225553940
Laurent.crenier@erasme.ulb.ac.be

Supplementary figure: The Gold score: this impaired awareness of hypoglycaemia questionnaire asked questions such as “do you know when your hypos are starting?” The respondent completed a 7-point Likert scale, with 1 representing “always aware” and 7 representing “never aware”. A score of ≥ 3 implied impaired awareness of hypoglycaemia. This visual scale uses emoticons to suit all ages.



Supplementary table: Changes in parameters during the study: within group comparisons

	Intervention (RT-CGM, n=19)			Control (FGM, n=18)			Delta [†]
Parameters	Baseline	End	P-value	Baseline	End	P-value	P-value
HbA1c, %	7.6 (7.0 – 8.7)	7.6 (7.0 – 8.5)	NS	8.1 (7.4 – 8.3)	7.9 (7.3 – 8.3)	NS	NS
Gold score positivity, n (%)	10 (53)	7 (37)	NS	10 (56)	8 (44)	NS	NS
Participants with SH, n (%)	5 (26)	1 (5)	NS	3 (17)	3 (17)	NS	NS
Episodes of SH, n	0 (0 – 1)	0 (0 – 0)	0.043	0 (0 – 0)	0 (0 – 0)	NS	NS
TBR 24 h*, %	10 (4 – 12)	7 (4 – 12)	NS	8 (4 – 12)	10 (3 – 11)	NS	NS
TBR 24 h <4%*, n (%)	4 (22)	4 (31)	NS	4 (25)	7 (39)	NS	NS
TBR wake*, %	9 (6 – 11)	7 (2 – 9)	NS	6 (3 – 12)	7 (4 – 11)	NS	NS
TBR sleep*, %	9 (3 – 13)	6 (1 – 10)	NS	5 (1 – 12)	3 (0 – 14)	NS	NS
Time below 54 mg/d 24 h*, %	4 (2 – 5)	2 (1 – 5)	NS	3 (1 – 5)	2 (1 – 4)	NS	NS
Time below 54 mg/dl wake*, %	2 (0 – 5)	2 (0 – 6)	NS	2 (0 – 5)	2 (0 – 4)	NS	NS
Time below 54 mg/dl sleep*, %	2 (0 – 5)	1 (0 – 5)	NS	0 (0 – 2)	0 (0 – 2)	NS	NS
Time in target range*, %	52 (39 – 63)	50 (34 – 58)	NS	48 (37 – 55)	47 (41 – 60)	NS	NS
Time above 180 mg/dl*, %	43 (23 – 51)	41 (28 – 62)	NS	42 (34 – 54)	41 (28 – 53)	NS	NS
Time above 250 mg/dl*, %	17 (8 – 26)	19 (10 – 33)	NS	17 (9 – 27)	20 (8 – 25)	NS	NS
Coefficient of variation*, %	45 (40 – 52)	41 (38 – 49)	NS	42 (37 – 51)	41 (35 – 47)	NS	NS

* From Envision

† Comparison between groups (CGM vs. FGM) using delta, that is, median change from baseline

- All values are shown as median (IQR) excluding severe hypoglycaemia, gold score positivity, and TBR < 4% as n (%).
- RT-CGM, real-time continuous glucose monitoring; FGM, flash glucose monitoring; SH, severe hypoglycaemia; TBR, time below range, < 70 mg/dl; NS, not significant
- Comparisons within groups were performed using the paired Wilcoxon rank sum test or McNemar test (gold score positivity, severe hypoglycaemia, TBR < 4%). Comparisons between groups (CGM vs FGM) were performed using Wilcoxon-Mann-Whitney test, X² test or Fisher's exact test depending on the subgroup size